Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Stage Cell Therapeutics, Juno Therapeutics deal

    Stage Cell Therapeutics GmbH, Goettingen, Germany Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Business: Gene/Cell therapy, Biomanufacturing Juno acquired cell therapy manufacturing company Stage Cell …

    Published on 5/18/2015
  • TetraLogic, Merck deal

    TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Cancer TetraLogic and Merck will jointly conduct a Phase I trial evaluating TetraLogics …

    Published on 5/18/2015
  • Alkermes, Recro deal

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Business: Neurology Recro completed its purchase of IV/IM meloxicam and its related business unit and manufacturing facility from…

    Published on 5/11/2015
  • Astellas, Vical deal

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Vical Inc. (NASDAQ:VICL), San Diego, Calif. Business: Infectious Astellas granted Vical exclusive, worldwide rights to develop and commercialize ASP2397. Astellas will …

    Published on 5/11/2015
  • Athersys, Cell Therapy Catapult deal

    Athersys Inc. (NASDAQ:ATHX), Cleveland, Ohio Cell Therapy Catapult, London, U.K. Business: Gene/Cell therapy, Pulmonary In January, Athersys and Cell Therapy Catapult partnered to evaluate Athersys MultiStem in a U.K. …

    Published on 5/11/2015
  • Auspex, Teva deal

    Auspex Pharmaceuticals Inc., La Jolla, Calif. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology Teva completed its acquisition of neurology play Auspex for $101 per share in cash, …

    Published on 5/11/2015
  • Azellon, Cell Therapy Catapult, NHS Blood and Transplant, University of Liverpool deal

    Azellon Ltd., London, U.K. Cell Therapy Catapult, London, U.K. NHS Blood and Transplant (NHSBT), Hertfordshire, U.K. University of Liverpool, Liverpool, U.K. Business: Gene/Cell therapy, Musculoskeletal Azellon, Cell …

    Published on 5/11/2015
  • Berg, Beth Israel Deaconess, Cancer Research and Biostatistics deal

    Berg LLC, Farmingham, Mass. Beth Israel Deaconess Medical Center, Boston, Mass. Cancer Research and Biostatistics, Seattle, Wash. Business: Cancer, Pharmacogenetics The partners will identify and develop biomarkers for …

    Published on 5/11/2015
  • Cannabics, Technion - Israel Institute of Technology deal

    Cannabics Pharmaceuticals Inc. (Pink:CNBX), Bethesda, Md. Technion - Israel Institute of Technology, Haifa, Israel Business: Cancer Cannabics and Technion partnered to develop a diagnostic system to screen anticancer …

    Published on 5/11/2015
  • Case Western Reserve University, Tracon deal

    Case Western Reserve University, Cleveland, Ohio Tracon Pharmaceuticals Inc. (NASDAQ:TCON), San Diego, Calif. Business: Cancer The partners added more patents to a 2006 deal granting Tracon rights to certain patents, …

    Published on 5/11/2015
  • Catalyst Biosciences, Wyeth deal

    Catalyst Biosciences Inc., South San Francisco, Calif. Wyeth, Madison, N.J. Business: Hematology Pfizer Inc. (NYSE:PFE, New York, N.Y.) will exercise its right to terminate a 2009 deal granting Wyeth, now part of Pfizer…

    Published on 5/11/2015
  • Celexion, Agenus deal

    Celexion LLC, Cambridge, Mass. Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Business: Antibodies Agenus purchased Celexions Secant yeast display discovery platform to generate mAbs, the companys IgG antibody library, …

    Published on 5/11/2015
  • Cell Therapy Catapult, Plasticell, University of Oxford deal

    Cell Therapy Catapult, London, U.K. Plasticell Ltd., London, U.K. University of Oxford, Oxford, U.K. Business: Gene/Cell therapy, Biomanufacturing, High throughput screening Cell Therapy Catapult, Plasticell and the …

    Published on 5/11/2015
  • City of Hope, Fortress Biotech deal

    City of Hope, Duarte, Calif. Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Business: Infectious City of Hope granted Fortress newly formed DiaVax Biosciences subsidiary exclusive, worldwide rights to develop and …

    Published on 5/11/2015
  • EpiTherapeutics, Gilead deal

    EpiTherapeutics ApS, Copenhagen, Denmark Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Cancer Gilead acquired epigenetics company EpiTherapeutics for $65 million in cash. EpiTherapeutics is …

    Published on 5/11/2015
  • Evotec, Asahi Kasei deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Asahi Kasei Corp. (Tokyo:3407), Tokyo, Japan Business: Pharmaceuticals Evotec will use its ion channel platform to identify inhibitors of multiple ion channel targets provided by …

    Published on 5/11/2015
  • Fate Therapeutics, Juno Therapeutics deal

    Fate Therapeutics Inc. (NASDAQ:FATE), San Diego, Calif. Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Business: Gene/Cell therapy Fate granted Juno worldwide rights to develop and commercialize engineered T cell …

    Published on 5/11/2015
  • Genomics, Eisai deal

    Genomics plc, Oxford, U.K. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Pharmaceuticals The partners will use Genomics statistical analyses of multi-phenotype genetic association data to inform Eisais drug …

    Published on 5/11/2015
  • Hannover Medical School, Ipsen deal

    Hannover Medical School, Hannover, Germany Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Business: Neurology, Cancer, Endocrine/Metabolic Ipsen and Hannover partnered to develop therapeutics for …

    Published on 5/11/2015
  • Helsinn, Mundipharma deal

    Helsinn Healthcare S.A., Lugano, Switzerland Mundipharma International Ltd., Cambridge, U.K. Business: Endocrine/Metabolic The companies added China, including Hong Kong and Macau, to a February deal granting …

    Published on 5/11/2015
  • Hyperion, Horizon Pharma deal

    Hyperion Therapeutics Inc., South San Francisco, Calif. Horizon Pharma plc (NASDAQ:HZNP), Dublin, Ireland Business: Endocrine/Metabolic Horizon completed its acquisition of rare disease company Hyperion for $46 per …

    Published on 5/11/2015
  • Isis Pharmaceuticals, Bayer deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Hematology Isis granted Bayer exclusive, worldwide rights to develop and commercialize ISIS-FXIRx to prevent…

    Published on 5/11/2015
  • Isis Pharmaceuticals, Biogen Idec deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Biogen Idec Inc., Cambridge, Mass. Business: Neurology Isis received a $10 million milestone payment from Biogen under a 2013 deal under which the companies are …

    Published on 5/11/2015
  • Lanthio Pharma, MorphoSys deal

    Lanthio Pharma B.V., Groningen, the Netherlands MorphoSys AG (Xetra:MOR;Pink:MPSYF), Martinsried, Germany Business: Renal MorphoSys acquired the remaining 80% of Lanthio it did not already own for EUR20 million ($22.3 …

    Published on 5/11/2015
  • Padlock Therapeutics, NIH deal

    Padlock Therapeutics Inc., Cambridge, Mass. National Institutes of Health, Bethesda, Md. Business: Autoimmune Padlock and NIH partnered to investigate the role of Padlocks peptidyl arginine deiminase (PADI; PAD) …

    Published on 5/11/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993